Evidence map›Paper›PMID 39983682›Full record

Trial reportEmerging infectious diseases2025

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.

Josephine Bourner, Michel Vaillant, Alex Paddy Abdel Salam, Marie Jaspard, Camille Fritzell, Shevin T Jacob, Tom E Fletcher, Michael Ramharter, Nnennaya Ajayi, Sylvanus Okogbenin and 9 more

Abstract readClinical Trial, Phase IIEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Ending Lassa neglect: the urgent case for a licensed vaccine.Annals of medicine and surgery (2012) · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Josephine Bourner
Michel Vaillant
Alex Paddy Abdel Salam
Marie Jaspard
Camille Fritzell
Shevin T Jacob
Tom E Fletcher
Michael Ramharter
Nnennaya Ajayi
Sylvanus Okogbenin
Cyril Erameh
Donald Grant
Robert Samuels
Oladele Oluwafemi Ayodeji
Armand Sprecher
Bronner P Gonçalves
Tansy Edwards
Piero Olliaro
WALC Work Package 2 Working Group

Funding

Wellcome Trust
6 · The paper itself

Abstract

The current recommendation for treating Lassa fever with ribavirin is supported only by weak evidence. Given the persistent effects in areas with endemic transmission and epidemic potential, there is an urgent need to reassess ribavirin and investigate other potential therapeutic candidates; however, a robust clinical trial method adapted to Lassa fever epidemiology has not yet been established. We propose an adaptive phase II/III multicenter randomized controlled platform trial that uses a superiority framework with an equal allocation ratio and accounts for challenges selecting the primary end point and estimating the target sample size by using an interim analysis.

Indexed as

Antiviral AgentsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicLassa FeverRibavirinHumansLassa virusMulticenter Studies as TopicRandomized Controlled Trials as TopicResearch DesignAntiviral AgentsRibavirinclinical trialsLassa feverphase II/III multicenter randomized controlled platform trialviruses

Identifiers

PMID39983682
PMCPMC11845141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.